Drug intelligence / Profile preview

FFP-102

Development stage: Discontinued
Lead developer: Fast Forward Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FFP-102 is a monoclonal antibody developed by Fast Forward Pharmaceuticals as a CD40 pathway antagonist. It is designed to block the interaction between the CD40 receptor and its ligand, CD154 (also known as CD40L), which is a critical costimulatory pathway in immune activation. By inhibiting this interaction, FFP-102 aims to suppress the pathogenic immune responses and inflammatory signaling characteristic of autoimmune disorders such as Crohn's disease. Although initially part of the Fast Forward Pharmaceuticals pipeline, the drug's development appears to have stalled or been discontinued following the company's inactivity after 2019.

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on FFP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FFP-102.

Explore the full profile